Trending Now
ISW Holdings Inc (OTCMKTS:ISWH) New Telehealth Business Just Got Good News
While telehealth is a powerful revolution according to basically everyone on the planet right now, and one that’s likely to be here and dominant...
Top Cannabis Ideas as Pot Stocks Become Deep Value Investment Theme...
The recession shade is casting a pall over the US equities market over recent weeks (1). More Wall Street houses are starting...
Value Builds in Select Crypto Mining Stocks (HIVE, BLQC, RIOT, MARA,...
Wells Fargo is now forecasting a recession in the US – the first US-based major bank to come out with that analysis...
Popular News
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Receives Rare Pediatric Disease Designation For...
Axovant Gene Therapies Ltd (NASDAQ:AXGT) recently announced that it was awarded rare disease designation for AXO-AAV-GM2, a gene therapy that it has been developing...
MAKE IT MODERN
LATEST REVIEWS
Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) And Cheisi Submit BLA for PRX-102 in...
Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) and Chiesi Global Rare Diseases have announced that they have submitted a Biologics License Application to the FDA for pegunigalsidase...
MAKE IT MODERN
PERFORMANCE TRAINING
The US FDA Reclassifies Eyenovia Inc.’s (NASDAQ: EYEN) MyCombi Formulation As A Drug-Device
Eyenovia Inc. (NASDAQ: EYEN) has announced the reclassification of its novel first-in-class microdose formulation combination of phenylephrine and tropicamide for in-office pupil dilation, MydCombi,...
Dare Biosciences Inc. (NASDAQ:DARE) Reports Positive DARE-BV1 Study Results In Bacterial Vaginosis Treatment
Dare Biosciences Inc. (NASDAQ:DARE) has announced encouraging top-line DARE-BVFREE Third Phase double-blinded, randomized, placebo-controlled clinical study results. The study evaluated the company's DARE-BV1 in...
Why the EV Pullback Could be a Once-in-a-Lifetime Opportunity for Investors (TSLA, DSGT, XPEV,...
If there’s one stat that really shows the growth potential in the electric vehicle space over coming years, it’s this: EVs accounted...
Curis, Inc. (NASDAQ: CRIS) Recently Announced Its Partners’ Publication on Emarvusatib
Curis, Inc. (NASDAQ: CRIS) recently announced the publication of a report created by the company's collaborators. The school of Medicine from Washington University authored...
IDEAYA Biosciences Inc. (NASDAQ:IDYA) And GlaxoSmithKline Plc (NYSE:GSK) In Strategic Partnership For Synthetic Lethality...
IDEAYA Biosciences Inc. (NASDAQ:IDYA) has announced a strategic partnership with GlaxoSmithKline Plc (NYSE:GSK) in Synthetic lethality, which is an emerging Oncology field.
IDEAYA’s Synthetic Lethality...
MAKE IT MODERN
[/tdc_zone]